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Polycystin-1 expression in PKD1, early-onset PKD1, and tations in one of three genes: PKD1, the major gene
TSC2/PKD1 cystic tissue. accounting for 85 to 90% of cases, and PKD2 or PKD3,
Background. The mutational mechanism responsible for accounting for the remaining 10 to 15%. The identifica-cyst formation in polycystic kidney disease 1 gene (PKD1)
tion of PKD1 in 1994 [1] and PKD2 in 1996 [2] hasremains controversial, with data indicating a two-hit mecha-
provided new tools to study the biology of cyst formationnism, but also evidence of polycystin-1 expression in cystic
tissue. in this disease. The PKD1 protein, polycystin-1, is
Methods. To investigate this apparent paradox, we analyzed thought to be a membrane glycoprotein (approximately
polycystin-1 expression in cystic renal or liver tissue from 10 460 kDa) involved in cell adhesion [3, 4], whereas thepatients with truncating PKD1 mutations (including one early-
PKD2 protein has homology to a family of voltage-gatedonset case) and 2 patients with severe disease associated with
sodium/calcium channels [2]. Sequence similarities alsocontiguous deletions of TSC2 and PKD1, using monoclonal
antibodies (mAbs) to both extreme N-(7e12) and C-terminal indicate that polycystin-1 may play a role in ion transport
(PKS-A) regions of the protein. Truncation of the C-terminal [5]. Recent studies showing that these two proteins have
epitope from the putative mutant proteins in each case allowed a similar cellular distribution [6] and can interact in ex-exclusive assessment of the nontruncated protein with PKS-A.
perimental systems [7, 8] are consistent with the pheno-Results. In adult PKD1 tissue, the majority of cysts (approxi-
typic similarity of both conditions.mately 80%) showed polycystin-1 expression, although staining
was absent in a variable but significant minority (approximately In spite of the cloning of PKD1, the mutational mecha-
20%), in spite of the normal expression of marker proteins. nism underlying cyst initiation remains controversial. Ev-
Unlike adult PKD1, however, negative cysts were rarely found idence is accumulating that germline PKD1 mutationsin infantile PKD1 or TSC2/PKD1 deletion cases.
are probably inactivating. First, although relatively fewConclusions. If a two-hit mutational mechanism is opera-
mutations have been described, those characterized aretional, these results suggest that the majority of somatic muta-
tions in adult PKD1 are likely to be missense changes. The mainly predicted to terminate the protein prematurely
low level of polycystin-1–negative cysts in the three “early- because of the introduction of a stop or frameshifting
onset” cases, however, suggests that a somatic PKD1 mutation change [9–11]. Second, an analysis of a group of patientsmay not always be required for cyst formation.
with deletions disrupting PKD1 and the adjacent tuber-
ous sclerosis gene TSC2 [12, 13] shows that PKD1 is
often completely deleted and a phenotype of tuberousAutosomal dominant polycystic kidney disease
sclerosis with severe, early-onset polycystic kidney dis-(ADPKD) is the most common genetic disease affecting
ease results. Although the contribution that disruptionthe kidney and accounts for up to 10% of patients on
of a single TSC2 allele makes to the cystic phenotype isrenal replacement therapy. ADPKD can result from mu-
unclear, these cases show that a null PKD1 allele can
result in cyst formation. Finally, a severe cystic pheno-
type manifesting in late fetal life has been observed inKey words: polycystic kidney disease, ADPKD, TSC2, gene mutations,
cystogenesis. the Pkd1del34/del34 knockout mouse [14], indicating that cyst
formation is associated with the complete absence ofReceived for publication December 15, 1998
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lial cells derived from single ADPKD cysts are clonal in size the N-terminal mAb, 7e12, 471 bp of PKD1 (281-
origin [15] and that between 17 and 24% of cysts exhibit 751nt) was cloned into the pET15b expression vector
loss of heterozygosity (LOH) at PKD1 [15, 16]. Recently, to generate a fusion protein. Hybridomas were initially
evidence of inactivating point mutations in liver cystic screened against an Fc chimeric protein containing the
tissue has also been described [17]. These results suggest same region of the protein (synthesized in COS-1 cells)
that an inactivating germline mutation only results in by enzyme-linked immunosorbent assay (ELISA). Posi-
cyst formation once the normal allele is disrupted by tive clones were then screened for their ability to detect
somatic mutation. A “two-hit” model is an attractive Fc chimeric proteins either containing the 7e12 epitope,
explanation for the focal nature of cyst formation and LRR (212-802nt) and Nter (90-2747nt), or excluding that
the phenotypic variability of cystic disease in PKD1. region, lectin (1396-1823nt) by immunoblotting.
Additional support for this hypothesis has come from The 7e12 epitope is encoded by a region of the PKD1
mice carrying a targeted disruption of PKD2 [18]. Immu- gene duplicated in the homologous genes (HGs) [1].
nohistological analysis shows that unlike the surrounding Recent sequence data of two HGs (AC002039), how-
normal noncystic tubules, cysts formed in Pkd21/2 ani- ever, indicate that these loci could only encode small
mals do not express polycystin-2, indicating that PKD2 truncated products (approximately 50 kDa; unpublished
cysts only develop in the absence of the protein. In addi- observation), and Western analysis with 7e12 has failed
tion, a hypermutable allele with tandemly inserted exon 1 to reveal any such proteins. It therefore seems likely that
sequences (WS-25) was found to develop cysts at a higher any such HG products are unstable and that 7e12 is
rate than the corresponding heterozygote (Pkd2WS25/2 de- polycystin-1 specific.
velops more cysts than Pkd21/2), suggesting that cysto-
genesis is associated with somatic mutation. Recently, Plasma membrane preparation from tissues
more detailed descriptions of mice carrying a targeted Plasma membrane fractions of normal human adult
disruption of Pkd1 have shown that a variable number kidney cortex (obtained at nephrectomy) were prepared
of cysts are found in older Pkd11/2 mice, a finding similar by a modification of established methods [26]. Pieces of
to that seen in Pkd21/2 mice. Interestingly, however, in tissue were first thawed, cut into fine pieces, and homoge-
this case, not all cysts in Pkd11/2 mice lacked polycystin-1 nized in buffer 1 (0.01 m Tris-HCl, pH 7.4, 0.25 m sucrose,
expression, as assessed with a monoclonal antibody 0.2 mm CaCl2) using a polytron homogenizer. The ho-(mAb) to PKD1 (PKS-A) [19]. mogenate was diluted with ice-cold buffer 2 [0.01 m Tris-
At first glance, a two-hit mechanism appears incom- HCl, pH 7.4, 0.025 m sucrose, 1 mm ethylenediaminetet-
patible with results obtained from studies of polycystin-1 raacetic acid (EDTA)] and filtered through surgical
expression in ADPKD cystic renal tissue [20–24]. All of
gauze, and the suspension was centrifuged at 2000 g. Thethe published immunohistological studies (using differ-
resulting supernatant was then loaded onto a 35% (wt/ent antibodies) have found continued polycystin-1 ex-
vol) sucrose (buffer 3) cushion in SW28 tubes and centri-pression—often at a high level—in cystic epithelia [25],
fuged again at 30,000 g at 48C for 30 minutes. The inter-although in all but one case [20] the germline mutation
face was collected, diluted with buffer 4 (0.01 m Tris-of the tissue examined has not been identified.
HCl, pH 7.4, 0.25 m sucrose), and centrifuged finally atIn an effort to resolve this apparent conflict, we have
100,000 g at 48C for 45 minutes. The final pellet, a plasmaidentified and examined cystic renal tissue obtained from
membrane-enriched fraction, was resuspended in 0.5 tonine patients with defined truncating PKD1 mutations,
1.0 ml of buffer 4 or 1% sodium dodecyl sulfate (SDS)eight with adult-onset PKD1, one with early-onset PKD1,
and aliquots frozen at 2708C until analysis. Proteaseand two patients with contiguous deletions of TSC2 and
inhibitors (aprotinin 2 mg/ml, benzamide 1 mm, EDTAPKD1. Cystic PKD1 liver was obtained from one patient
1 mm, phenylmethylsulfonyl fluoride (PMSF) 1 mm,with a defined PKD1 mutation. In each case, the germ-
pepstatin 4 mg/ml, leupeptin 1 mg/ml, and pefablockline mutation truncates the C-terminal region of the mu-
1 mg/ml; Boehringer Mannheim, Germany) were addedtant protein; hence, by using a mAb raised to a C-terminal
to the buffers at all stages of the procedure.epitope of polycystin-1, we reasoned that the presence
or absence of the PKD1 protein encoded by the nontrun-
Western blottingcated allele could be assayed in individual cysts.
Cell pellets (2 3 107 cells) were harvested by scraping
in ice-cold PBS in the presence of protease inhibitors.
METHODS Total cell lysates were prepared from these pellets under
Production and characterization of monoclonal denaturing (boiling 1% SDS, 10 mm Tris-HCl, pH 7.4)
antibodies to epitopes in the duplicated and unique or native (RIPA buffer: 150 mm NaCl, 1% NP-40, 0.5%
regions of polycystin-1 DOC, 0.1% SDS, 50 mm Tris-HCl, pH 7.5) conditions.
The protein content of each sample was measured usingThe synthesis and screening of the C-terminal mAb
PKS-A have been previously described [20]. To synthe- a microtiter Lowry assay (Bio-Rad, Richmond, CA,
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USA). Each sample (total cell lysate or plasma mem-
brane fraction) was resuspended in an equal volume of
2 3 Laemmli sample buffer (100 mm Tris-HCl, pH 6.8,
4% SDS, 20% glycerol, 0.1% bromophenol blue, 5%
b-mercaptoethanol) and incubated at 378C for 30 min-
utes or 958C for five minutes prior to loading. SDS-
polyacrylamide gel electrophoresis was performed on
7.5% separating gels using a Bio-Rad Mini Protean II
apparatus using molecular weight standards (Rainbow;
Amersham, Bucks, UK) with a range of 14.3 to 220
kDa. Separated proteins were then transferred at 30 V
overnight or 100 V for one hour onto a polyvinylidine
difluoride (PVDF) membrane (Millipore, Bedford, MA,
USA). In some experiments, gels were stained with Coo-
masie, either in parallel to assess migration or after trans-
fer to assess transfer efficiency.
Filters were blocked with 5 to 10% nonfat milk in
Tris-buffered saline (TBS, pH 7.6) overnight, probed
with the primary antibody for one hour, and a horserad-
ish peroxidase (HRP)-conjugated secondary antibody
(goat antimouse or goat antirabbit) for one hour. Filters
were washed extensively with TBS (with added Tween
0.05%) after detection with each antibody. Bound sec-
ondary antibody was detected by enhanced chemilumi-
nescence (ECL; Boehringer) using Kodak film.
Clinical details of PKD1 and TSC2/PKD1 patients
Renal tissue was obtained from eight PKD1 patients
with typical adult-onset disease and cystic liver from 1
PKD1 patient, in whom truncating PKD1 mutations
have been identified (Fig. 1 and Table 1). The mutations
in OX18, OX40, and OX1330 have been described pre-
viously [1, 10, 20]. Full characterization of the other
mutations is described elsewhere (Rossetti, manuscript
in preparation).
A case of early-onset PKD1 was also identified in
Oxford (OX1005), the fetus being born at term (40 week
female) but dying two hours after birth with massively
enlarged kidneys (courtesy of Dr. S. Gould, John Rad-
Fig. 1. Diagram of the polycystic kidney disease-1 (PKD1) protein,cliffe Hospital, Oxford, UK). We have subsequently
polycystin-1, showing the position of defined PKD1 mutations in 12
identified the mutation in this PKD1 family (Fig. 1 and patients, in whom renal or liver tissue was available for analysis. (Open
arrows) In these patients, the regions C-terminal of the arrow areTable 1).
removed because of DNA deletion: TSC2/PKD1 (16 and III1) or typicalRenal tissue from two patients with known deletions
PKD1 (OX1330). The III1 breakpoint has been localized to the area
of TSC2 and PKD1 were also obtained: 16 (courtesy of bracketed. (Filled arrows) The point at which polycystin-1 is predicted
to be terminated in typical PKD1 patients; OX1005 had early-onsetProfessor M. Barrett and Professor R.A. Risdon, Insti-
PKD1. The monoclonal antibodies (7e12, PKS-A) were raised to thetute of Child Health, London, UK) and III1 (courtesy
regions of the protein highlighted in gray.
of Dr. R. Tardanico and Dr. F. Scolari, Spedali Civili,
Brescia, Italy). The mutation in both of these patients
has been described previously [13, 27]. The position of
the proximal breakpoint in III1 has been refined to lie Supplies, Aylesbury, UK) and a graded series of alcohol
solutions. For immunoperoxidase detection, endogenousbetween exons 18 to 24.
peroxidase was blocked by a 30-minute incubation in a
Immunohistochemistry 0.5% hydrogen peroxide/methanol solution. Nonspecific
binding was blocked with 10% goat serum, and tissuesParaffin sections (5 mm) were cut onto Vectabond-
coated slides and deparaffinized through Citroclear (HD were incubated sequentially with primary and HRP-con-
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Table 1. Polycystin-1 immunoreactivity in PKD1, TSC2/PKD1 and early-onset PKD1 kidneys
1 Cysts 2 Cysts 6 Cysts
Total
Patient Pedigree Mutation cysts N % N % N %
Adult onset PKD1 kidney OX161 P18 E1537X 19 13 2 4
OX31 P314 4784delG 19 12 3 4
OX35 P9 6645del28 24 13 11 0
OX3 P17 Q2243X 23 21 2 0
OX4 P7 C2370X 33 25 7 1
OX1330 P95 10708del5.5kb 18 17 0 1
OX40 P187 Q3513X 33 21 7 5
OX18 P225 12739delA 22 11 7 4
Totals 191a 133 69.6 39 20.4 19 10
Adult onset PKD1 liver OX1162 P164 6356insG 24 14 58.1 5 20.8 5 20.8
Adult onset PKD1 Totals 215 147 68.3 44 20.5 24 11.2
Early onset PKD1 OX1005 P118 8126dup20 11b 11 100 0 0 0
TSC-2/PKD1 III1 FAM1 del175kb 16 15 1 0
16 2895del26kb 10 10 0 0
Totals 26 25 96.2 1 3.8 0
a 119 cysts (62.3%) of the cysts counted were of . 2 mm in diameter
b No cysts . 2 mm were found
jugated secondary antibodies for 30 to 60 minutes. Bound Materials
secondary antibody was detected with diaminobenzid- A mAb to utrophin (MANCHO7) was the kind gift
ine (Sigma, St. Louis, MO, USA), and the nuclei were of Professor Glenn Morris (NE Wales Institute, Clwyd,
counterstained with hematoxylin. Sections were then Wales, UK). Mouse mAbs employed were to the a1
mounted in Depex mountant (BDH) after dehydration subunit of rabbit Na1-K1-ATPase, cross-reactive with
through a series of ethanol and xylene solutions. As the human protein (Upstate Biotechnology, Lake Placid,
negative controls tissue sections were incubated without NY, USA) and to Epithelial Membrane Antigen (EMA;
the primary antibody or with an aliquot of antibody that Sigma, Poole, UK). TRITC-conjugated PNA was pur-
had been preincubated overnight with 5 to 10 mg of the chased from Vector Labs (Burlingame, CA, USA).
fusion protein containing the epitope to which it had
been raised.
RESULTSTo determine the pattern of staining in each patient,
all cysts of more than 1 mm in diameter were counted Production and characterization of a monoclonal
on all tissue available and were graded for staining inten- antibody to the LRR domain of polycystin-1
sity and epithelial morphology in a single blinded fashion
To complement the existing mAb to the C terminusby an experienced renal pathologist (D.R.D.). A cyst
(PKS-A) [20], a mAb to the flank-leucine rich repeat-(cystically dilated tubule or Bowman’s capsule) was de-
flank region (24-180aa) was produced (Fig. 1). The speci-fined as an abnormal epithelial lined cavity with dimen-
ficity of this antibody (7e12) was initially tested for itssions wider than 1 mm (that is, greater than five times
ability to recognize Fc fusion proteins containing differ-the normal tubular diameter). For the purposes of quan-
ent regions of polycystin-1 that either included or ex-titation, cysts were excluded if no epithelial lining was
cluded the LRR domain by immunoblotting (Fig. 2A).observed or if the lumen appeared to communicate with
Second, we examined the affinity of 7e12 for nativetransitional epithelium. Cyst lining epithelium was de-
polycystin-1 in a range of renal cell lines. The highestscribed morphologically as attenuated, bosselated, papil-
level of expression was found in COS-1 cells, with alary, cuboidal, or columnar.
band of approximately 400 kDa (similar to the predictedImmunofluorescence was performed as detailed for
polycystin-1 molecular weight) detected (Fig. 2A). Simi-the immunoperoxidase method except that a FITC-con-
larly sized proteins were detected in membrane fractionsjugated goat antimouse secondary antibody (Cappel,
of normal human kidney (Fig. 2B). The approximateDurham, NC, USA) was used. Where dual staining with
size of polycystin-1 was confirmed by detection of a simi-a fluorescent-conjugated lectin (for example, peanut ag-
lar-sized endogenous protein, utrophin (400 kDa), inglutinin; PNA) and PKD1 mAb was performed, lectin
COS-1 cells by immunoblotting (data not shown).binding preceded the blocking step. Stained sections
Finally, to see if 7e12 would identify a novel band inwere mounted in Moviol and imaged using a CCD cam-
Western analysis of cells containing a PKD1 mutation,era on an epifluorescence microscope with a mercury
fibroblasts from the 77 family, in which PKD1 is dis-lamp and appropriate filter sets for fluorescein and rho-
damine. rupted in exon 15 by a chromosomal translocation [1],
Ong et al: Polycystin-1 expression in PKD1 cystic tissue1328
Fig. 2. Characterization of the N-terminal polycystin-1 monoclonal antibody (mAb) 7e12 by immunoblotting. (A) Recombinant proteins (10 ng)
containing regions of polycystin-1: C-type lectin (398-539aa; 32 kDa), leucine-rich repeats (LRR; 1-197aa; 35 kDa) and N-terminal region (Nter;
1-845aa; 103 kDa), and COS-1 cell lysate (50 mg) detected with 7e12. 7e12 identified the approximately 400 kDa endogenous protein in COS-1
cells (and other renal cell lines; data not shown) and recombinant molecules containing the LRR domain. The proteins detected in the LRR and
Nter samples are larger than predicted from the amino acid composition, probably because of glycosylation. A larger protein detected in the LRR
sample may reflect oligomerization of the LRR Fc protein. (B) A doublet approximately 400 kDa polycystin-1 product is detected with 7e12 in
plasma membrane-enriched fractions isolated from two normal kidneys (NK1 and NK2; 50 mg). The a1 subunit of Na1,K1-ATPase (100 kDa)
was also strongly detected in these membrane fractions, showing enrichment for plasma membrane proteins (data not shown). (C) Cell lysates of
COS-1 cells, skin fibroblasts of a normal control (Fib) and from two patients with a chromosomal translocation disrupting PKD1 (77-2 and 77-4
[1]; 50 mg) detected with 7e12. The endogenous polycystin-1 is detected in COS-1, but not normal fibroblasts. A mutant polycystin-1 molecule
approximately 300 kDa is detected in the translocation containing cells.
were examined (Fig. 2C). Although polycystin-1 is not Polycystin-1 expression in normal adult human kidney
normally detected in fibroblasts, the same novel sized Analysis of normal human adult kidney with PKS-A
band (approximately 300 kDa) was detected in two mem- (and 7e12) revealed polycystin-1 expression localizing
bers of this family with the translocation, consistent with predominantly, although not exclusively, to a subset of
the size predicted from the transcript (approximately 8 cortical tubules and medullary collecting ducts, which
kb) detected in these individuals [1]. It is not clear why are also PNA and EMA positive [6]. This distal pattern
of expression in the adult kidney is distinct from thea novel polycystin-1 molecule is expressed in these cells
more generalized expression of polycystin-1 by bothwhen the normal protein is not. However, previous stud-
proximal and distal nephron segments in fetal kidneyies have shown that this abnormal transcript is very sig-
that we have previously reported [20].nificantly up-regulated [1] and may reflect the different
chromosomal environment, deletion of the normal 39 end
Polycystin-1 expression assessed with PKS-A and 7e12
of the gene (which encodes the transmembrane region of
in adult PKD1 kidneys and liver with characterized
the protein) and/or the presence of a novel C-terminal truncating deletions
end. Nevertheless, this analysis clearly illustrates the af-
Previous analysis of ADPKD epithelia with the mAbfinity of 7e12 for polycystin-1. Preliminary attempts to
PKS-A showed staining of cystic epithelia, including indetect the presence of other mutant polycystin-1 proteins
one patient with a known deletional mutation (OX1330),from PKD1 cystic tissue with 7e12 have thus far been
which removed the PKS-A epitope [20]. We have fol-
unsuccessful.
lowed up this study by analyzing renal tissue from seven
PKS-A does not detect the native protein in COS-1 other patients with known truncating mutations: OX3,
cells by Western blotting under all conditions attempted, OX4, OX18, OX31, OX35, OX40, and OX161 (Table 1
but does detect a recombinant protein containing the and Fig. 1). Each mutation is predicted to generate a
terminal 1225aa of polycystin-1 in transfected COS-1 mutant protein lacking the PKS-A epitope; thus, only
cells, as previously described [20]. The reason for this protein encoded by the other allele would be detected
difference is unclear but may represent the lower affinity with this antibody (the mutation in OX18 removes only
of PKS-A for native polycystin-1, as compared with 7e12 part of the region used to synthesize PKS-A; Fig. 1). A
(and thus the inability to detect the much lower levels systematic analysis of these cases is shown in Table 1,
normally seen), or be due to a conformation-restricted which illustrates that the majority of cysts (approxi-
mately 70%) show clear immunoreactivity for the PKD1recognition of the epitope.
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protein (Figs. 3 and 4). Nevertheless, some cysts (approx- was rarely observed in these two cases (Fig. 4 and
Table 1).imately 20%) were negative for polycystin-1: The distri-
bution of these negative cysts was nonuniform and varied
Polycystin-1 expression in early-onset PKD1 kidneyfrom patient to patient (Table 1). No consistent correla-
A case of early-onset PKD1 with a characterized trun-tion with a specific epithelial cell morphology was de-
cating mutation (OX1005; Fig. 1) was also analyzed. Oftected, although, in general, negative staining for poly-
interest, both glomerular and tubular cysts were presentcystin-1 was more frequently observed in cysts with an
in this patient, although no cysts of more than 2 mmattenuated cell lining; less commonly, some cysts with a
were identified (Fig. 4). Again, unlike adult-onset PKD1,cuboidal or bosselated lining were also negative (Figs.
no negative cysts could be identified (Fig. 4 and Table3 and 4). In a minority of cysts (approximately 10%),
1). In four other cases of early-onset PKD1 (data notheterogeneous polycystin-1 expression was detected
shown), negative cysts were also rarely observed, but in(Fig. 3). In approximately half of these cysts, negative
these cases, the germline mutation could not be identi-staining in an otherwise positive cyst lining correlated
fied, so they have not been included in this analysis.with a region of the cyst where the epithelial morphology
of the cell lining changed abruptly to an attenuated form.
In other cysts, positive cells could be observed in an DISCUSSION
otherwise negative cyst lining and vice versa. A similar This study of polycystin-1 expression in PKD1 cystic
expression pattern was found in the one PKD1 liver tissue was initially prompted by uncertainty about the
available for analysis (OX1162), except that the propor- mutational mechanism in PKD1 and, in particular, the
tion of heterogenous cysts detected was higher (approxi- apparent inconsistency between observations of LOH in
mately 20%) and that of positive cysts lower (approxi- isolated renal cyst epithelia and immunohistochemical
mately 60%) than in the cases of cystic kidney (Fig. 4 studies of polycystin-1 in cystic tissue [25]. To address
and Table 1). specifically the question as to whether polycystin-1 pro-
To analyze the pattern of staining more precisely, sec- tein encoded by the “normal” PKD1 allele was present
tions were either dually stained with the lectin PNA and in individual cysts, we limited our analysis to PKD1 cystic
a polycystin-1 mAb or serial sections were stained with tissue obtained from patients in whom germline muta-
a polycystin-1 mAb and a mAb to EMA. PNA and EMA tions truncating the C-terminal region of polycystin-1
are segment-specific markers for distal cortical tubules had been identified. Using a mAb raised to the C-termi-
and collecting ducts in normal human kidney [28, 29], nal region of polycystin-1, PKS-A, we found that overall,
although EMA expression may be induced in injured 70% of cysts were positive in adult-onset cases, indicating
proximal tubules [30]. Not all cysts were EMA or PNA the presence of protein encoded by the “normal” allele.
positive, confirming previous observations that cysts may These results are consistent with previous immunohisto-
arise from different nephron segments [28]. Figure 3 chemical studies of cystic epithelia that showed that
A–C shows an example of a cyst lining that is not stained polycystin-1 immunoreactivity can be detected in the
with PKS-A but is PNA positive; normal tubules are majority of cysts [20–24], although in these cases, linkage
stained with both. Heterogenous polycystin-1 expression to PKD1 was not always established, and moreover, the
was observed in small and large cysts. An example of a germline mutation was unknown.
cyst that binds PNA uniformly but that shows differential In this study, we also observed a proportion of cysts
expression of polycystin-1 can be seen in Figure 3 G–I. (approximately 20%) that are negative for polycystin-1
Cysts or cystic regions found to be negative with PKS-A when stained with PKS-A. The absence of polycystin-1
were also negative with 7e12, confirming the absence in these cysts could be due to somatic mutations that
of the entire protein (Fig. 4). Staining of all cysts was delete or truncate the “normal” PKD1 allele, consistent
abolished by preincubation of the polycystin-1 mAb with the results obtained from the analysis of isolated
(PKS-A, 7e12) with the relevant fusion protein (data not cyst epithelia [15–17]. Interestingly, we have also found
shown). that cysts negative for PKS-A were also nearly always
negative with 7e12, a mAb generated to the N-terminus
Polycystin-1 expression in TSC2/PKD1 cystic epithelia of polycystin-1. Because an N-terminal antibody should
A rare subgroup of patients providing a unique insight in theory detect mutant polycystin-1 proteins in most
into the pathophysiology of cyst formation are cases with cases analyzed (Fig. 1), this result indicates that these
deletions disrupting PKD1 and TSC2, resulting in early- proteins may become unstable when truncated (dis-
onset PKD [13]. We have studied two such TSC2/PKD1 cussed later in this section).
deletion cases in which much of the PKD1 gene is deleted No consistent relationship between epithelial mor-
(Fig. 1 and Table 1; discussed in the Methods section). phology and polycystin-1 expression was observed, al-
though cysts with an attenuated cell lining were moreUnlike adult PKD1, negative polycystin-1 expression
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Fig. 3. Dual fluorescent staining of PKD1 kidneys with a mAb to the C-terminus of PKD1, PKS-A (FITC, green), and the lectin PNA (TRITC,
red). Renal tissue was obtained from three patients with mutations truncating the C-terminus of polycystin-1: OX3 (A-C), OX161 (D-F), and
OX40 (G-I). Polycystin-1 staining is shown in (A, D, and G), PNA reactivity in (B, E, and H), and dual color images of each section in (C, F,
and I). (A–C) Note the polycystin-1–negative cuboidal cyst lining (arrows) that is PNA positive in OX3. Some PNA and polycystin-1 positive
tubules are also seen. (D–F) Note the expression of polycystin-1 in two adjoining large PNA positive cysts (arrows) in OX161. Both cysts have
an attenuated epithelial lining. (G–I) In contrast to uniform PNA reactivity, heterogenous staining for polycystin-1 is seen in a finger-like projection
in OX40. These heterogenous cysts comprised approximately 10% of all cysts counted (magnification 3200).
b
often negative, and those with a cuboidal lining were rupting the DNA-binding domain [31], and may, in addi-
tion, have a dominant negative effect by binding to themore often positive. However, many examples of posi-
tive attenuated cysts and negative cuboidal cysts were normal protein [34]. Thus, it is possible that the high
level of polycystin-1 we see in the majority of PKD1observed (Figs. 3 and 4). Polycystin-1 negativity could
not be explained entirely by “de-differentiation” because cysts may be due to an accumulation of inactive protein.
In the light of this, it is of interest that using thenegative cysts often, although not always, express other
proteins such as EMA or PNA, which are expressed by N-terminal mAb 7e12, we were able to detect a mutant
polycystin-1 protein of predicted size in skin fibroblastsmature distal tubules and collecting ducts. Polycystin-1
expression was also noted in EMA- or PNA-negative of two individuals with PKD from a family in which
PKD1 is disrupted in exon 15 by a chromosome translo-cysts, implying that cysts arising from other nephron
segments also express polycystin-1. Thus, it is unlikely cation. Unfortunately, we do not know if this protein is
expressed in the kidney because no renal tissue or cellsthat polycystin-1–negative cysts have arisen from poly-
cystin-1–negative tubular segments. This is consistent were available from this family for further study. This
is the first time a mutant polycystin-1 protein has beenwith previous studies showing that in ADPKD, renal
cysts may arise from proximal, distal, and other nephron demonstrated, and although interesting, it is probable
that this is a unique situation because the mutant PKD1segments [28].
Our results could be reconciled with a two-hit mecha- transcript is highly overexpressed compared with the
levels for the normal allele [1]. Moreover, in preliminarynism initiating cystogenesis if the majority of somatic
mutations are missense, with a variable but smaller pro- studies, we have not been able to detect mutant
polycystin-1 proteins in other adult-onset PKD1 patientsportion of stop, frame-shifting changes or deletions (in-
cluding LOH). Missense mutations could functionally with defined germline mutations.
Like others, we have observed a proportion of cystsinactivate the “normal” polycystin-1 protein while allow-
ing its expression and detection. Although the majority (approximately 10%) with partial staining for poly-
cystin-1. In half of these cysts, it was evident that aof germline PKD1 mutations that have been identified
so far are stop or frame-shifting changes (in part due to positive region abuts onto a negative region (Fig. 3G),
often where the morphology of the cyst epithelium hadthe methods used to specifically detect such changes),
the spectrum of somatic changes may be quite different. also changed abruptly (for example, from columnar or
bosselated to attenuated). The most likely explanationThe situation may be analogous to that found with muta-
tions of the tumor suppressor gene p53 in many tumors. for this is that two different cysts have fused. In other
cysts, positive and negative cells were found adjacent toMost p53 mutations changes are missense [31] and are
associated with a high level of p53 when monitored by each other, a preliminary finding also reported by others
(abstract; Droz et al, J Am Soc Nephrol 8:371, 1997). Itimmunohistochemistry [32] caused by the increased sta-
bility of the mutant protein [33]. Nevertheless, these is unlikely that this type of patchy staining represents
LOH and may be due to changes in polycystin-1 expres-missense changes inactivate the protein, often by dis-
b
Fig. 4. Immunoperoxidase staining for polycystin-1 and EMA in PKD1 kidney; OX40 (A–F), PKD1 liver; OX1162 (G), TSC2/PKD1 kidney; 16
(H); III1 (I) and early-onset PKD1; OX1005 (J–L). Sequential sections from OX40 stained with PKS-A (A and D), 7e12 (B and E), or EMA (C
and F) showing the presence (A and B) or absence (D and E) of polycystin-1 staining with both mAbs in EMA positive cysts. Note the cuboidal
epithelium in both positive (A–C) and negative (D–F) cysts and the expression of polycystin-1 by both EMA-positive and -negative tubules in
A–C. The liver cysts displayed from OX1162 (G) shows polycystin-1 expression (PKS-A) in several biliary microhamartoma and part of an
attenuated negative cyst lining (arrows). Prominent expression of polycystin-1, as detected by PKS-A, in cystic and normal tubular epithelium of
both patients with a TSC2/PKD1 deletion 16 (H) and III1 (I) was observed. An identical expression pattern was seen in both patients with 7e12
(data not shown). Note the increased cytoplasmic to nuclear ratio typically seen in these cystic cells involving TSC2 disruption [13] (arrows) and
the area of papillary outgrowth in the cyst lining illustrated (I). In OX1005, both glomerular (J) and tubular cysts (K and L) express polycystin-1
as detected by PKS-A (J and K) or 7e12 (L; magnification 3100 for all except 3200; I). Glomeruli (g), cysts (c), and tubules (t) are indicated.
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sion, perhaps dependent on the stage of cell division or PKD1, however, points to the possibility of a different
mutational mechanism.other intracellular factors. Similar changes have been
observed for p53 in tumors and may be more evident in
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